Using our proprietary Enhanced Design and Combine (EDC) chemistry platform, we are developing an emerging portfolio of novel designer immunotherapies for the treatment of cancer and autoimmune diseases.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    20-49
Key business